HPN217 is a BCMA-targeting tri-specific t-cell activating construct (TriTAC) in development for patients with multiple myeloma.
| SparkCures ID | 367 |
|---|---|
| Developed By | Harpoon Therapeutics |
| Generic Name | HPN217 |
| Treatment Classifications |
|
| Treatment Targets |
|
View all active clinical trials around the US.
The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.